| Literature DB >> 31139232 |
Liselot Koelman1,2, Olga Pivovarova-Ramich3,4,5,6, Andreas F H Pfeiffer3,4,5, Tilman Grune7, Krasimira Aleksandrova1,2.
Abstract
BACKGROUND: There is a growing interest in the role of inflammageing for chronic disease development. Cytokines are potent soluble immune mediators that can be used as target biomarkers of inflammageing; however, their measurement in human samples has been challenging. This study aimed to assess the reliability of a pro- and anti-inflammatory cytokine panel in a sample of healthy people measured with a novel electrochemiluminescent multiplex immunoassay platform (Meso Scale Discovery, MSD), and to characterize their associations with metabolic and inflammatory phenotypes.Entities:
Keywords: Ageing; BMI; Biomarkers; Cytokines; Inflammaging; Multiplex platforms; Reliability
Year: 2019 PMID: 31139232 PMCID: PMC6530020 DOI: 10.1186/s12979-019-0151-1
Source DB: PubMed Journal: Immun Ageing ISSN: 1742-4933 Impact factor: 6.400
Baseline characteristics of the study population, overall and by sex
|
|
|
| |
|---|---|---|---|
|
| 56.7 (53.7, 59.5) | 57.6 (55.8, 60.4) | 55.4 (51.5, 58.9) |
| Range | 44.8–63.9 | 51.5–63.7 | 44.8–63.9 |
|
| 26.1 (23.3, 28.8) | 27.8 (25.3, 29.5) | 25.0 (22.6, 27.9) |
| Range | 19.1–41.7 | 19.8–37.0 | 19.1–41.7 |
| Overweight, BMI > 25 (%) | 61 | 78 | 50 |
|
| 93.0 (83.8, 101.8) | 100.8 (96.1, 107.5) | 86.3 (77.6, 93.3) |
| Range | 68.3–126.3 | 79.3–126.3 | 68.3–115.8 |
| 1.2 (0.7, 2.5) | 1.5 (0.7, 2.9) | 1.1 (0.6, 2.2) | |
| Range | 0.1–13.4 | 0.1–12.9 | 0.2–13.4 |
|
| 136.0 (128.0, 144.0) | 137.0 (130.0, 145.0) | 134.8 (124.0, 142.0) |
| Range | 100.0–206.0 | 100.0–206.0 | 100.0–163.0 |
|
| 88.0 (80.0, 94.0) | 90.0 (85.0, 96.0) | 86.0 (79.0, 92.0) |
| Range | 62.0–120.0 | 62.0–120.0 | 67.0–106.0 |
|
| 1.0 (0, 2.5) | 0.5 (0, 2.0) | 1.0 (0, 3.0) |
| Range | 0–14.0 | 0–12.0 | 0–14.0 |
|
| 1.0 (0, 3.0) | 0 (0, 2.0) | 1.0 (0, 3.0) |
| Range | 0–14.0 | 0–12.0 | 0–14.0 |
| Non-fasting (%) | 10 | 13 | 8 |
Abbreviations: BMI Body mass index, hsCRP High sensitivity C-reactive protein. Values are expressed as medians (25th, 75th percentile), or percentages
Repeated measurements of the cytokine concentrations, overall and by sex, with estimated ICCs
|
|
|
| P |
| |||
|---|---|---|---|---|---|---|---|
| N | Median (IQR) | N | Median (IQR) | ||||
|
| ALL | 79 | 3.12 (0.35–6.50) | 82 | 3.00 (0.39–5.45) | 0.89 | 0.25 (0.02, 0.44) |
| Men | 31 | 2.71 (0.35–4.42) | 30 | 3.27 (0.23–6.25) | 0.72 | 0.28 (−0.11, 0.57) | |
| Women | 48 | 3.47 (0.44–7.18) | 52 | 2.97 (0.53–5.18) | 0.92 | 0.23 (−0.07, 0.47) | |
| 0.32 | 0.77 | ||||||
|
| ALL | 143 | 2.13 (0.21–6.47) | 131 | 1.77 (0.19–5.23) | 0.72 | 0.32 (0.16, 0.46) |
| Men | 59 | 2.32 (0.21–6.23) | 56 | 2.15 (0.21–4.66) | 0.93 | 0.26 (0.00, 0.48) | |
| Women | 84 | 1.67 (0.20–6.52) | 75 | 0.56 (0.19–6.37) | 0.62 | 0.36 (0.15, 0.54) | |
| 0.82 | 0.83 | ||||||
|
| ALL | 143 | 2.66 (1.53–5.75) | 152 | 2.75 (1.57–5.98) | 0.94 | −0.18 (−0.34, −0.02) |
| Men | 56 | 2.69 (1.52–6.02) | 60 | 2.70 (1.47–5.49) | 0.78 | −0.23 (−0.47, 0.02) | |
| Women | 87 | 2.63 (1.53–5.61) | 92 | 2.90 (1.65–6.15) | 0.64 | −0.15 (−0.35, 0.06) | |
| 0.92 | 0.78 | ||||||
|
| ALL | 207 | 0.52 (0.41–0.79) | 207 | 0.52 (0.40–0.71) | 0.06 | 0.60 (0.51, 0.68) |
| Men | 83 | 0.59 (0.44–0.82) | 83 | 0.60 (0.44–0.81) | 0.55 | 0.51 (0.34, 0.66) | |
| Women | 124 | 0.50 (0.37–0.76) | 124 | 0.47 (0.38–0.68) | 0.04 | 0.63 (0.51, 0.72) | |
| 0.02 | 0.001 | ||||||
|
| ALL | 207 | 3.91 (3.10–4.88) | 207 | 3.89 (2.99–5.02) | 0.32 | 0.64 (0.55, 0.71) |
| Men | 83 | 3.96 (3.19–4.96) | 83 | 4.19 (3.20–5.62) | 0.07 | 0.62 (0.47, 0.74) | |
| Women | 124 | 3.67 (3.03–4.73) | 124 | 3.62 (2.81–4.74) | 0.81 | 0.63 (0.51, 0.73) | |
| 0.14 | 0.004 | ||||||
|
| ALL | 207 | 0.25 (0.18–0.34) | 207 | 0.25 (0.18–0.34) | 0.76 | 0.58 (0.48, 0.66) |
| Men | 83 | 0.28 (0.19–0.36) | 83 | 0.26 (0.19–0.35) | 0.03 | 0.38 (0.18, 0.55) | |
| Women | 124 | 0.24 (0.17–0.31) | 124 | 0.24 (0.18–0.33) | 0.13 | 0.72 (0.63, 0.80) | |
| 0.02 | 0.35 | ||||||
|
| ALL | 194 | 0.30 (0.15–6.01) | 203 | 0.31 (0.16–6.01) | 0.98 | 0.35 (0.22, 0.47) |
| Men | 78 | 1.90 (0.13–6.69) | 81 | 1.06 (0.14–6.00) | 0.29 | 0.27 (0.05, 0.46) | |
| Women | 116 | 0.22 (0.15–5.32) | 122 | 0.27 (0.16–6.20) | 0.30 | 0.40 (0.24, 0.54) | |
| 0.31 | 0.87 | ||||||
|
| ALL | 167 | 0.67 (0.43–0.92) | 168 | 0.77 (0.52–1.04) | 0.01 | 0.43 (0.30, 0.55) |
| Men | 69 | 0.55 (0.41–0.76) | 67 | 0.63 (0.44–0.97) | 0.12 | 0.43 (0.21, 0.60) | |
| Women | 98 | 0.75 (0.49–0.20) | 101 | 0.83 (0.61–1.08) | 0.06 | 0.39 (0.21, 0.54) | |
| 0.01 | 0.01 | ||||||
|
| ALL | 207 | 3.06 (2.12–4.61) | 207 | 3.06 (2.18–4.21) | 0.43 | 0.40 (0.28, 0.51) |
| Men | 83 | 2.81 (2.09–4.29) | 83 | 2.82 (2.06–3.87) | 0.66 | 0.28 (0.07, 0.46) | |
| Women | 124 | 3.37 (2.16–4.86) | 124 | 3.26 (2.22–4.44) | 0.46 | 0.48 (0.33, 0.61) | |
| 0.28 | 0.14 | ||||||
|
| ALL | 207 | 1.94 (1.56–2.39) | 207 | 1.96 (1.57–2.40) | 0.07 | 0.70 (0.63, 0.77) |
| Men | 83 | 2.04 (1.64–2.40) | 83 | 2.14 (1.60–2.50) | 0.44 | 0.77 (0.66, 0.84) | |
| Women | 124 | 1.87 (1.51–2.36) | 124 | 1.87 (1.56–2.33) | 0.10 | 0.65 (0.53, 0.74) | |
| 0.07 | 0.08 | ||||||
*P value for difference based on Wilcoxon signed rank test between first and second measurements. **P value for difference based on Wilcoxon rank sum test between men and women (Kruskal Wallis) Abbreviations: ICC Intraclass correlation coefficient, IQR Interquartile range, CI Confidence interval
Fig. 1Bland-Altman plots showing the agreement between log-transformed cytokine concentrations at baseline and 4-months later in relation to average concentrations for each individual. Agreement of repeated measurements (y-axis) in relation to average concentrations (x-axis) for each individual. Horizontal lines show the mean difference and the 95% CI of limits of agreement, which are defined as the mean difference +/− 1.96 times the standard deviation of the differences
Fig. 2Box plots visualizing the distributions of log transformed cytokine concentrations stratified by age tertiles. This figure represents distributions of interleukin 1-beta (IL-1β), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 10 (IL-10), interleukin 12p70 (IL-12p70), interleukin 13 (IL-13), interferon gamma (IFN-γ), and tumor necrosis factor alpha (TNF-α) according to increasing age categories (red: 44.9–54.7 years, green: 54.8–58.8 years, and purple: 58.9–64.0 years). Concentrations are from plasma samples collected during the first measurement
Correlations for cytokine concentrationsa with BMI, WC, hsCRP, and sports adjusted for age and sex
| Biomarker | BMI (kg/cm2) | Waist Circumference (cm) | hsCRP (ug/ml) | Reported sports activitiesb (hours/week) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | ρc | 95% CId | N | ρc | 95% CId | N | ρc | 95% CId | N | ρc | 95% CId | |
|
| 102 | −0.19 | − 0.37, 0.01 | 102 | −0.15 | − 0.33, 0.05 | 76 | 0.06 | −0.17, 0.28 | 79 | 0.09 | −0.14, 0.3 |
| 0.06 | 0.15 | 0.62 | 0.46 | |||||||||
|
| 159 | 0.04 | −0.11, 0.2 | 159 | 0.08 | −0.07, 0.24 | 126 | −0.02 | − 0.2, 0.15 | 143 | 0.07 | −0.1, 0.23 |
| 0.59 | 0.30 | 0.78 | 0.42 | |||||||||
|
| 175 | −0.06 | −0.21, 0.09 | 175 | −0.06 | −0.21, 0.09 | 137 | 0.03 | −0.14, 0.2 | 143 | 0.03 | −0.14, 0.19 |
| 0.44 | 0.69 | 0.42 | 0.76 | |||||||||
|
| 207 | 0.36 | 0.23, 0.47 | 207 | 0.41 | 0.28, 0.51 | 164 | 0.53 | 0.41, 0.63 | 207 | −0.12 | −0.26, 0.01 |
| <.0001 | <.0001 | <.0001 | 0.08 | |||||||||
|
| 207 | 0.05 | −0.08, 0.19 | 207 | 0.04 | −0.1, 0.18 | 164 | 0.06 | −0.1, 0.21 | 207 | 0 | −0.14, 0.14 |
| 0.44 | 0.58 | 0.46 | 0.98 | |||||||||
|
| 207 | 0 | −0.14, 0.13 | 207 | 0.02 | −0.12, 0.15 | 164 | 0.19 | 0.03, 0.33 | 207 | 0.04 | −0.1, 0.17 |
| 0.96 | 0.82 | 0.02 | 0.60 | |||||||||
|
| 205 | 0.06 | −0.08, 0.19 | 205 | 0.10 | −0.04, 0.23 | 162 | −0.02 | − 0.17, 0.14 | 194 | 0.07 | −0.08, 0.21 |
| 0.43 | 0.16 | 0.82 | 0.36 | |||||||||
|
| 191 | 0.06 | −0.09, 0.2 | 191 | 0.06 | −0.09, 0.2 | 152 | 0.12 | −0.04, 0.28 | 167 | 0.04 | −0.12, 0.19 |
| 0.44 | 0.45 | 0.14 | 0.63 | |||||||||
|
| 207 | 0.04 | −0.1, 0.17 | 207 | 0.09 | −0.05, 0.22 | 164 | 0.23 | 0.08, 0.37 | 207 | 0.01 | −0.12, 0.15 |
| 0.60 | 0.22 | 0.004 | 0.84 | |||||||||
|
| 207 | 0.20 | 0.07, 0.33 | 207 | 0.16 | 0.03, 0.29 | 164 | 0.22 | 0.07, 0.36 | 207 | −0.15 | −0.28, −0.02 |
| 0.004 | 0.02 | 0.004 | 0.03 | |||||||||
aMean cytokine concentrations from both measurements bSports in winter with first blood sample from October–March. cSpearman partial correlation coefficient. dBased on Fisher’s z transformation Abbreviations: BMI Body mass index, CI Confidence interval, hsCRP High sensitivity c-reactive protein, IL-1β Interleukin 1-beta, IL-2 Interleukin 2, IL-4 Interleukin 4, IL-8 Interleukin 8, IL-10 Interleukin 10, IL-12p70 Interleukin 12p70, IL-13 Interleukin 13, IFN-γ Interferon gamma, IQR Interquartile range, TNF-α Tumor necrosis factor alpha, WC Waist circumference
ICCs with 95% CIs of inflammatory cytokines in predominantly healthy participants previously published in literature
| Reference | Assay | Cytokines | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IL-1β | IL-2 | IL-4 | IL-6 | IL-8 | IL-10 | IL-12p70 | IL-13 | IFN-γ | TNF- | ||
| This study | MSD | 0.25 (0.02, 0.44) | 0.32 (0.16, 0.46) | −0.18 (− 0.34, − 0.02) | 0.60 (0.51, 0.68) | 0.64 (0.55, 0.71) | 0.58 (0.48, 0.66) | 0.35 (0.22, 0.47) | 0.43 (0.30, 0.55) | 0.40 (0.28, 0.51) | 0.70 (0.63, 0.77) |
| McKay et al. 2017 [ | MSD | ND | ND | – | 0.60 (0.51, 0.68) | – | 0.85 (0.81, 0.88) | 0.84 (0.79, 0.87) | – | ND | 0.54 (0.46, 0.63) |
| Belzeaux et al. 2017 [ | MSD | ND | – | ND | 0.04 | −0.01 | 0.12 | 0.83 | ND | 0.07 | 0.74 |
| Luminex | 0.96 | – | 0.90 | 0.95 | 0.89 | 0.96 | 0.89 | 0.90 | 0.97 | 0.96 | |
| Epstein et al. 2013 [ | Luminex | 0.49 (0.41, 0.62) | – | – | 0.55 (0.47, 0.62) | 0.34 (0.25, 0.43) | 0.70 (0.64, 0.75) | – | – | 0.55 (0.47, 0.62) | 0.87 (0.84, 0.90) |
| Todd et al. 2013 [ | Erenna Immunoassay Systema | – | – | – | 0.46 | – | – | – | 0.39 | ||
| Nash et al. 2013 [ | ELISA | – | – | – | 0.72 | – | – | – | – | – | – |
| Navarro et al. 2012 [ | ELISA/ Luminexb | – | – | – | 0.48 (0.36, 0.62) | 0.73 (0.63, 0.83) | – | – | – | – | 0.92 (0.89, 0.96) |
| Hofmann et al. 2011 [ | Luminex | ND | ND | ND | 0.84 (0.70, 0.91) | 0.55 (0.28, 0.71) | 0.60 (0.35, 0.76) | ND | 0.73 (0.52, 0.85) | ND | 0.86 (0.74, 0.93) |
| Clendenen et al. 2010 [ | Luminex | 0.73 (0.43, 0.89) | 0.80 (0.56, 0.92) | 0.70 (0.36, 0.87) | 0.81 (0.56, 0.92) | 0.86 (0.68, 0.95) | 0.75 (0.46, 0.90) | 0.77 (0.50, 0.91) | 0.81 (0.56, 0.92) | 0.72 (0.41, 0.89) | 0.69 (0.36, 0.87) |
| Gu et al. 2009 [ | Luminex | 0.86 (0.78, 0.91) | 0.81 (0.71, 0.88) | 0.92 (0.87, 0.95) | 0.92 (0.88, 0.95) | 0.02 (0.00, 0.21) | 0.75 (0.63, 0.84) | 0.83 (0.74, 0.89) | – | – | 0.88 (0.82, 0.92) |
| Lee et al. 2007 [ | Luminex | 0.77 | – | – | 0.73 | 0.51 | – | – | – | – | 0.48 |
aLaboratory developed tests based upon single-molecule counting technology. bIL-6 was measured with ELISA, IL-8 and TNF-α with Luminex. Abbreviations: ICC Intraclass correlation coefficient, IL-1β Interleukin 1-beta, IL-2 Interleukin 2, IL-4 Interleukin 4, IL-8 Interleukin 8, IL-10 Interleukin 10, IL-12p70 Interleukin 12p70, IL-13 Interleukin 13, IFN-γ Interferon gamma, MSD Meso Scale Discovery, TNF-α Tumor necrosis factor alpha, ND Not determined for analytes with low % detected (usually < 40% samples above LLOD or high coefficients of variability of duplicates)
Fig. 3Flow diagram of the study design. A total of 207 participants (124 women and 83 men) from the EPIC-Potsdam Cohort completed this study. Single blood samples were collected on two occasions, 4 months apart